Late-life estrogen therapy linked to lower dementia risk in women

A large study following more than 21,000 women has found that estrogen-only hormone therapy taken later in life was linked to a measurably lower risk of developing dementia and showing signs of Alzheimer's disease in the brain. The research, published in the journal Neurology, examined medical records and clinical data from two separate groups of women, tracking them over three to five years beginning at an average age of 71. Some participants underwent brain imaging or biomarker testing while alive; others had their brains examined at autopsy after death, typically around age 82, to look for the telltale pathological markers of Alzheimer's.

Of the 21,462 women in the study, 1,953 had used hormone therapy—nearly all of them beginning after age 70—while 19,509 had not. The researchers focused specifically on estrogen-only therapy rather than combination estrogen-progestin formulations, because earlier studies had suggested the combination might actually increase dementia risk. Estrogen-only therapy is currently prescribed mainly to women who have had a hysterectomy, since estrogen alone carries less risk of endometrial cancer than estrogen combined with progestin.

The autopsy findings were striking. Among women who had taken hormone therapy, 18 percent showed no signs of Alzheimer's disease in their brains at death, compared to just 10 percent of those who had never used the therapy. Conversely, 40 percent of hormone therapy users displayed all three hallmark pathological features of Alzheimer's disease, whereas 51 percent of non-users showed this full constellation of damage. When researchers adjusted their analysis for age, education, genetics, race, and high blood pressure, women who had used hormone therapy carried 35 percent lower odds of showing Alzheimer's pathology at autopsy.

A separate analysis using biomarker tests performed while women were still living pointed in the same direction. Those who had taken hormone therapy showed blood and spinal fluid levels of amyloid-beta protein that suggested less accumulation of this protein as plaques in the brain—a key feature of Alzheimer's disease. Women on hormone therapy also had 39 percent lower odds of receiving a clinical diagnosis of dementia and were less likely to report memory problems or functional decline.

Yet the researchers were careful to frame their findings as an association, not proof of prevention. Jennifer Bruno, the study's lead author from Stanford Medicine, emphasized that the women in this study had used hormone therapy decades ago, starting in their seventies—a pattern quite different from current medical practice, which typically begins hormone therapy in the late forties or early fifties and discontinues it before age 60. "While these findings help us better understand the relationship between hormone therapy use and various markers of dementia, more research needs to be done before we can make recommendations to women about their use of these therapies in relation to their brain health," Bruno said. She acknowledged that because the study population's hormone therapy use differed substantially from today's standard approach, the results may not directly apply to women considering or currently using these treatments under modern protocols.

The study opens a door to further investigation into how and why estrogen might protect the aging brain, but it does not yet provide a clear clinical directive. The timing of hormone therapy initiation, its duration, and the specific formulation all appear to matter—variables that future research will need to untangle before doctors can confidently counsel women on these medications as a strategy for brain health.